Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 24 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

6 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 3

5(26.3%)

N/A

5(26.3%)

Phase 2

4(21.1%)

Phase 1

2(10.5%)

Early Phase 1

2(10.5%)

Phase 4

1(5.3%)

19Total

Phase 3(5)

N/A(5)

Phase 2(4)

Phase 1(2)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials

NCT07083154Phase 3Recruiting

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

Role: collaborator

NCT05313529Not ApplicableActive Not Recruiting

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Role: collaborator

NCT06978738Phase 1Not Yet Recruiting

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Role: lead

NCT06964867Not ApplicableRecruiting

Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters

Role: lead

NCT06337474Early Phase 1Recruiting

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

Role: lead

NCT06898216Not ApplicableRecruiting

Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial

Role: collaborator

NCT06405113Phase 2Recruiting

FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer

Role: lead

NCT06403111Phase 2Recruiting

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

Role: lead

NCT06709378Completed

Effectiveness and Safety of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus

Role: lead

NCT06404281Phase 1Recruiting

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Role: lead

NCT06483594Not Yet Recruiting

Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)

Role: collaborator

NCT06379451Early Phase 1Not Yet Recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Role: lead

NCT05535829Unknown

Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients

Role: collaborator

NCT05179733Phase 3Unknown

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Role: collaborator

NCT04140552Unknown

Chinese Research Group of Gallbladder Cancer

Role: collaborator

NCT04554134Completed

The Hybrid Combination of CCTA and SPECT and CAG for Evaluation Prognosis of CAD: an Observational Follow-up Study

Role: collaborator

NCT04446130Phase 3Unknown

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Role: collaborator

NCT04087967Phase 3Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

Role: collaborator

NCT04083911Phase 3Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

Role: collaborator

NCT03766490Not ApplicableUnknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Role: collaborator